0001193125-23-267696.txt : 20231101 0001193125-23-267696.hdr.sgml : 20231101 20231101070800 ACCESSION NUMBER: 0001193125-23-267696 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231101 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231101 DATE AS OF CHANGE: 20231101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Revolution Medicines, Inc. CENTRAL INDEX KEY: 0001628171 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472029180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39219 FILM NUMBER: 231366537 BUSINESS ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 415-766-3638 MAIL ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 8-K 1 d527979d8k.htm 8-K 8-K
false 0001628171 0001628171 2023-11-01 2023-11-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 1, 2023

 

 

Revolution Medicines, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39219   47-2029180
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

700 Saginaw Drive

Redwood City, California

   94063
(Address of principal executive offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 481-6801

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☒

Written communications pursuant to Rule 425 under the Securities Act

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common stock, $0.0001 par value per share   RVMD   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01. Regulation FD Disclosure.

On November 1, 2023, Revolution Medicines, Inc. (“Revolution Medicines”) issued a press release to announce that Revolution Medicines and EQRx, Inc. (“EQRx”) have determined the final exchange ratio, described in Item 8.01 of this Current Report on Form 8-K, in accordance with the terms of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of July 31, 2023, by and among Revolution Medicines, Equinox Merger Sub I, Inc., a wholly owned subsidiary of Revolution Medicines (“Merger Sub I”), Equinox Merger Sub II LLC (“Merger Sub II”), a wholly owned subsidiary of Revolution Medicines, and EQRx, pursuant to which, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub I will be merged with and into EQRx (the “First Merger”), with EQRx surviving the First Merger as a direct, wholly owned subsidiary of Revolution Medicines (the “Surviving Corporation”), and as soon as practicable following the First Merger, the Surviving Corporation will be merged with and into Merger Sub II, with Merger Sub II surviving as a direct, wholly owned subsidiary of Revolution Medicines (together with the First Merger, the “Mergers”).

A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 8.01. Other Events.

On November 1, 2023, Revolution Medicines issued a press release to announce that Revolution Medicines and EQRx have determined the final exchange ratio in accordance with the terms of the Merger Agreement.

Pursuant to the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the First Merger, each share of common stock, par value $0.0001 per share, of EQRx (“EQRx Common Stock”) issued and outstanding immediately prior to the effective time will be converted into the right to receive 0.1112 of a share of common stock, par value $0.0001 per share, of Revolution Medicines (“Revolution Medicines Common Stock”). No fractional shares of Revolution Medicines Common Stock will be issued in the Mergers, and EQRx stockholders will receive cash in lieu of any fractional shares as part of the merger consideration, as specified in the Merger Agreement.

The final exchange ratio based on the actual determination date of October 31, 2023, is higher than the assumed exchange ratio of 0.0734 that was set out for illustrative purposes in the joint proxy statement/prospectus, dated September 29, 2023, that was filed by Revolution Medicines with the Securities and Exchange Commission (“SEC”) and previously distributed to Revolution Medicines and EQRx stockholders. If the Mergers are completed pursuant to the Merger Agreement, Revolution Medicines expects to issue approximately 55 million shares of Revolution Medicines Common Stock (excluding warrants and earn-out shares) in connection with the Mergers. The Company estimates that the Mergers will add approximately $1.1 billion in net cash proceeds, after estimated post-closing EQRx wind-down and transition costs, or approximately $20 per share of Revolution Medicines Common Stock issued in connection with the Mergers.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of management of Revolution Medicines and EQRx in light of historical results and trends, current conditions and potential future developments, and are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as “anticipate,” “expect,” “project,” “intend,” “believe,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “forecast,” “guidance,” “predict,” “possible,” “potential,” “pursue,” “likely,” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including express or implied statements regarding the proposed transaction; the conversion of equity interests contemplated by the Merger Agreement; the issuance of common stock of Revolution Medicines contemplated by the Merger Agreement; the expected timing of the closing of the proposed transaction; the ability of the parties to complete the proposed transaction considering the various closing conditions; the expected benefits of the proposed transaction; the competitive ability and position of the combined company; Revolution Medicines’ expectation to not advance EQRx’s research and development portfolio following closing of the proposed transaction; EQRx’s expectation to wind down its programs; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Revolution Medicines’ and EQRx’s plans, estimates or expectations described in such forward-looking statements could include, but are not limited to: (i) the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect Revolution Medicines’ and EQRx’s businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the proposed transaction; (iii) the potential failure to receive, on a timely basis or otherwise, the required approvals of the proposed transaction, including

stockholder approvals by both Revolution Medicines’ stockholders and EQRx’s stockholders, and the potential failure to satisfy the other conditions to the consummation of the transaction; (iv) that the proposed transaction may involve unexpected costs, liabilities or delays; (v) the effect of the announcement, pendency or completion of the proposed transaction on each of Revolution Medicines’ or EQRx’s ability to attract, motivate, retain and hire key personnel and maintain relationships with customers, distributors, suppliers and others with whom Revolution Medicines or EQRx does business, or on Revolution Medicines’ or EQRx’s operating results and business generally; (vi) that the proposed transaction may divert management’s attention from each of Revolution Medicines’ and EQRx’s ongoing business operations; (vii) the risk of any legal proceedings related to the proposed transaction or otherwise, or the impact of the proposed transaction thereupon, including resulting expense or delay; (viii) that Revolution Medicines or EQRx may be adversely affected by other economic, business and/or competitive factors; (ix) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement relating to the proposed transaction, including in circumstances which would require Revolution Medicines or EQRx to pay a termination fee; (x) the risk that restrictions during the pendency of the proposed transaction may impact Revolution Medicines’ or EQRx’s ability to pursue certain business opportunities or strategic transactions; (xi) the risk that Revolution Medicines or EQRx may be unable to obtain governmental and regulatory approvals required for the proposed transaction, or that required governmental and regulatory approvals may delay the consummation of the proposed transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; (xii) the risk that the anticipated benefits of the proposed transaction may otherwise not be fully realized or may take longer to realize than expected; (xiii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiv) risks relating to the value of Revolution Medicines securities to be issued in the proposed transaction; (xv) the risk that integration of the proposed transaction post-closing may not occur as anticipated or the combined company may not be able to achieve the growth prospects expected from the transaction; (xvi) the effect of the announcement, pendency or completion of the proposed transaction on the market price of the common stock of each of Revolution Medicines and the common stock and publicly traded warrants of EQRx; (xvii) the implementation of each of Revolution Medicines’ and EQRx’s business model and strategic plans for product candidates and pipeline, and challenges inherent in developing, commercializing, manufacturing, launching, marketing and selling potential existing and new products; (xviii) the scope, progress, results and costs of developing Revolution Medicines’ and EQRx’s product candidates and any future product candidates, including conducting preclinical studies and clinical trials, and otherwise related to the research and development of Revolution Medicines’ and EQRx’s pipeline; (xix) the timing and costs involved in obtaining and maintaining regulatory approval for Revolution Medicines’ and EQRx’s current or future product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product; (xx) the market for, adoption (including rate and degree of market acceptance) and pricing and reimbursement of Revolution Medicines’ and EQRx’s product candidates and their respective abilities to compete with therapies and procedures that are rapidly growing and evolving; (xxi) uncertainties in contractual relationships, including collaborations, partnerships, licensing or other arrangements and the performance of third-party suppliers and manufacturers; (xxii) the ability of each of Revolution Medicines and EQRx to establish and maintain intellectual property protection for products or avoid or defend claims of infringement; (xxiii) exposure to inflation, currency rate and interest rate fluctuations and risks associated with doing business locally and internationally, as well as fluctuations in the market price of each of Revolution Medicines’ and EQRx’s traded securities; (xxiv) risks relating to competition within the industry in which each of Revolution Medicines and EQRx operate; (xxv) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities; (xxvi) whether the termination of EQRx’s license agreements and/or discovery collaboration agreements may impact its or Revolution Medicines’ ability to license in additional programs in the future and the risk of delays or unforeseen costs in terminating such arrangements; (xxvii) risks that restructuring costs and charges may be greater than anticipated or incurred in different periods than anticipated; (xxviii) the risk that EQRx’s restructuring efforts may adversely affect its programs and its ability to recruit and retain skilled and motivated personnel, and may be distracting to employees and management; and (xxix) the risk that EQRx’s restructuring or wind-down efforts may negatively impact its business operations and reputation with or ability to serve counterparties or may take longer to realize than expected, as well as each of Revolution Medicines’ and EQRx’s response to any of the aforementioned factors. Additional factors that may affect the future results of Revolution Medicines and EQRx are set forth in their respective filings with the SEC, including each of Revolution Medicines’ and EQRx’s most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC’s website at www.sec.gov. See in particular Item 1A of Revolution Medicines’ Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 under the heading “Risk

Factors,” and Item 1A of each of EQRx’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2023 and June 30, 2023 under the headings “Risk Factors.” The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning Revolution Medicines and EQRx and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. Readers should also carefully review the risk factors described in other documents that Revolution Medicines and EQRx file from time to time with the SEC. Except as required by law, each of Revolution Medicines and EQRx assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Additional Information and Where to Find It

In connection with the proposed transaction, Revolution Medicines and EQRx filed with the SEC and mailed or otherwise provided to their respective security holders a joint proxy statement/prospectus regarding the proposed transaction (as amended or supplemented from time to time, the “Joint Proxy Statement/Prospectus”). INVESTORS AND REVOLUTION MEDICINES’ AND EQRX’S RESPECTIVE SECURITY HOLDERS ARE URGED TO CAREFULLY READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF REVOLUTION MEDICINES AND EQRX WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION.

Revolution Medicines’ investors and security holders may obtain a free copy of the Joint Proxy Statement/Prospectus and other documents that Revolution Medicines files with the SEC (when available) from the SEC’s website at www.sec.gov and Revolution Medicines’ website at ir.revmed.com. In addition, the Joint Proxy Statement/Prospectus and other documents filed by Revolution Medicines with the SEC (when available) may be obtained from Revolution Medicines free of charge by directing a request to Morrow Sodali LLC at RVMD@info.morrowsodali.com.

EQRx’s investors and security holders may obtain a free copy of the Joint Proxy Statement/Prospectus and other documents that EQRx files with the SEC (when available) from the SEC’s website at www.sec.gov and EQRx’s website at investors.eqrx.com. In addition, the Joint Proxy Statement/Prospectus and other documents filed by EQRx with the SEC (when available) may be obtained from EQRx free of charge by directing a request to EQRx’s Investor Relations at investors@eqrx.com.

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

Revolution Medicines, EQRx and their respective directors, executive officers, other members of management, certain employees and other persons may be deemed to be participants in the solicitation of proxies from the security holders of Revolution Medicines and EQRx in connection with the proposed transaction. Security holders may obtain information regarding the names, affiliations and interests of Revolution Medicines’ directors and executive officers in Revolution Medicines’ Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 27, 2023, and Revolution Medicines’ definitive proxy statement on Schedule 14A for its 2023 annual meeting of stockholders, which was filed with the SEC on April 26, 2023. To the extent holdings of Revolution Medicines’ securities by Revolution Medicines’ directors and executive officers have changed since the amounts set forth in such proxy statement, such changes have been or will be reflected on

subsequent Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC. Security holders may obtain information regarding the names, affiliations and interests of EQRx’s directors and executive officers in EQRx’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 23, 2023, and in certain of EQRx’s Current Reports on Form 8-K. To the extent holdings of EQRx’s securities by EQRx’s directors and executive officers have changed since the amounts set forth in such Annual Report on Form 10-K, such changes have been or will be reflected on subsequent Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such individuals in the proposed transaction is included in the Joint Proxy Statement/Prospectus relating to the proposed transaction filed with the SEC. These documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov, Revolution Medicines’ website at www.revmed.com and EQRx’s website at www.eqrx.com.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

 

99.1    Press Release, dated November 1, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    REVOLUTION MEDICINES, INC.
Date: November 1, 2023     By:  

/s/ Mark A. Goldsmith

    Name:   Mark A. Goldsmith, M.D., Ph.D.
    Title:   President and Chief Executive Officer
 EX-99.1 2 d527979dex991.htm EX-99.1 EX-99.1

EXHIBIT 99.1

 

LOGO

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend

Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112

REDWOOD CITY, Calif., November 1, 2023 – Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.

In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders. The acquisition will add the significant cash resources held by EQRx and strengthen Revolution Medicines’ balance sheet, allowing the company to sustain and retain control of its research and development plans for its RAS(ON) Inhibitor pipeline.

“We are pleased that ISS and Glass Lewis support our proposed acquisition of EQRx and the significant long-term value opportunity this compelling transaction provides to our stockholders,” said Mark A. Goldsmith, M.D., Ph.D., Revolution Medicines, chief executive officer and chairman. “The addition of approximately $1.1 billion to our balance sheet will increase our financial strength and enable robust investments to advance the clinical development of RMC-6236, our RASMULTI(ON) Inhibitor, RMC-6291, our RASG12C(ON) Inhibitor, and RMC-9805, our RASG12D(ON) Inhibitor. This transaction will also increase our capacity to develop our growing RAS(ON) Inhibitor pipeline in order to deliver high-impact targeted medicines to an even larger range of patients with RAS-addicted cancers.”

The company also today announced the final exchange ratio for the EQRx acquisition. Each share of common stock of EQRx issued and outstanding immediately prior to the merger will be converted into the right to receive 0.1112 shares of common stock of Revolution Medicines. If the transaction is completed, Revolution Medicines expects to issue approximately 55 million shares of its common stock in connection with the merger (excluding assumed warrants and earn-out shares). No fractional shares will be issued and EQRx stockholders will receive cash in lieu of any fractional shares as part of the merger consideration, as specified in the merger agreement with EQRx. The transaction is expected to close in November 2023, subject to satisfaction of customary closing conditions, including approval by both Revolution Medicines’ and EQRx’s stockholders. The company estimates that the acquisition will add approximately $1.1 billion in net cash proceeds, after estimated post-closing EQRx wind-down and transition costs, or approximately $20 per share of common stock issued in connection with the merger.

Special Meeting of Revolution Medicine Stockholders

The Revolution Medicines Board of Directors recommends Revolution Medicines stockholders vote “FOR” the issuance of shares in connection with the proposed transaction with EQRx. Revolution Medicines’ special meeting of stockholders is scheduled to take place virtually on Wednesday, November 8, 2023 at 8:00 a.m. PT. Only holders of record of Revolution Medicines common stock as of the close of business on September 26, 2023 are entitled to vote at the special meeting.

Stockholders who have questions or need assistance voting their shares should contact Revolution Medicines’ proxy solicitor, Morrow Sodali, LLC at (800) 662-5200 or (203) 658-9400 or by email at rvmd@info.morrowsodali.com.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-5127 (KRASG12V), RMC-0708 (KRASQ61H) and RMC-8839 (KRASG13C) which are currently in IND-enabling development, and additional compounds targeting other RAS variants.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of management of Revolution Medicines and EQRx in light of historical results and trends, current conditions and potential future developments, and are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as “anticipate,” “expect,” “project,” “intend,” “believe,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “forecast,” “guidance,” “predict,” “possible,” “potential,” “pursue,” “likely,” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including express or implied statements regarding the proposed transaction; the conversion of equity interests contemplated by the merger agreement; the issuance of common stock of Revolution Medicines contemplated by the merger agreement; the expected timing of the closing of the proposed transaction; the ability of the parties to complete the proposed transaction considering the various closing conditions; the expected benefits of the proposed transaction; the competitive ability and position of the combined company; Revolution Medicines’ development plans and timelines and its ability to advance its portfolio and research and development pipeline; progression of clinical studies and findings from these studies, including the tolerability and potential efficacy of Revolution Medicines’ candidates being studied; the potential advantages and effectiveness of Revolution Medicines’ clinical and preclinical candidates, including its RAS(ON) Inhibitors; the potential clinical utility of RMC-6236 in patients with non-small cell lung cancer and pancreatic cancer; the timing and completion of a clinical trial for the combination of RMC-6236 and RMC-6291; whether additional near-term and longer-term investments will strengthen the clinical advancement of Revolution Medicines’ RAS(ON) Inhibitors;

Revolution Medicines’ ability to enable seamless program progression; Revolution Medicines’ ability to advance its oncology assets and its intention to concentrate development resources on its three priority RAS-focused assets (RMC-6236, RMC-6291 and RMC-9805) following the proposed transaction; Revolution Medicines’ expectation to not advance EQRx’s research and development portfolio following closing of the proposed transaction; EQRx’s expectation to wind down its programs; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Revolution Medicines’ and EQRx’s plans, estimates or expectations described in such forward-looking statements could include, but are not limited to: (i) the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect Revolution Medicines’ and EQRx’s businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the proposed transaction; (iii) the potential failure to receive, on a timely basis or otherwise, the required approvals of the proposed transaction, including stockholder approvals by both Revolution Medicines’ stockholders and EQRx’s stockholders, and the potential failure to satisfy the other conditions to the consummation of the transaction; (iv) that the proposed transaction may involve unexpected costs, liabilities or delays; (v) the effect of the announcement, pendency or completion of the proposed transaction on each of Revolution Medicines’ or EQRx’s ability to attract, motivate, retain and hire key personnel and maintain relationships with customers, distributors, suppliers and others with whom Revolution Medicines or EQRx does business, or on Revolution Medicines’ or EQRx’s operating results and business generally; (vi) that the proposed transaction may divert management’s attention from each of Revolution Medicines’ and EQRx’s ongoing business operations; (vii) the risk of any legal proceedings related to the proposed transaction or otherwise, or the impact of the proposed transaction thereupon, including resulting expense or delay; (viii) that Revolution Medicines or EQRx may be adversely affected by other economic, business and/or competitive factors; (ix) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement relating to the proposed transaction, including in circumstances which would require Revolution Medicines or EQRx to pay a termination fee; (x) the risk that restrictions during the pendency of the proposed transaction may impact Revolution Medicines’ or EQRx’s ability to pursue certain business opportunities or strategic transactions; (xi) the risk that Revolution Medicines or EQRx may be unable to obtain governmental and regulatory approvals required for the proposed transaction, or that required governmental and regulatory approvals may delay the consummation of the proposed transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; (xii) the risk that the anticipated benefits of the proposed transaction may otherwise not be fully realized or may take longer to realize than expected; (xiii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiv) risks relating to the value of Revolution Medicines securities to be issued in the proposed transaction; (xv) the risk that integration of the proposed transaction post-closing may not occur as anticipated or the combined company may not be able to achieve the growth prospects expected from the transaction; (xvi) the effect of the announcement, pendency or completion of the proposed transaction on the market price of the common stock of each of Revolution Medicines and the common stock and publicly traded warrants of EQRx; (xvii) the implementation of each of Revolution Medicines’ and EQRx’s business model and strategic plans for product candidates and pipeline, and challenges inherent in developing, commercializing, manufacturing, launching, marketing and selling potential existing and new products; (xviii) the scope, progress, results and costs of developing Revolution Medicines’ and EQRx’s product

candidates and any future product candidates, including conducting preclinical studies and clinical trials, and otherwise related to the research and development of Revolution Medicines’ and EQRx’s pipeline; (xix) the timing and costs involved in obtaining and maintaining regulatory approval for Revolution Medicines’ and EQRx’s current or future product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product; (xx) the market for, adoption (including rate and degree of market acceptance) and pricing and reimbursement of Revolution Medicines’ and EQRx’s product candidates and their respective abilities to compete with therapies and procedures that are rapidly growing and evolving; (xxi) uncertainties in contractual relationships, including collaborations, partnerships, licensing or other arrangements and the performance of third-party suppliers and manufacturers; (xxii) the ability of each of Revolution Medicines and EQRx to establish and maintain intellectual property protection for products or avoid or defend claims of infringement; (xxiii) exposure to inflation, currency rate and interest rate fluctuations and risks associated with doing business locally and internationally, as well as fluctuations in the market price of each of Revolution Medicines’ and EQRx’s traded securities; (xxiv) risks relating to competition within the industry in which each of Revolution Medicines and EQRx operate; (xxv) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities; (xxvi) whether the termination of EQRx’s license agreements and/or discovery collaboration agreements may impact its or Revolution Medicines’ ability to license in additional programs in the future and the risk of delays or unforeseen costs in terminating such arrangements; (xxvii) risks that restructuring costs and charges may be greater than anticipated or incurred in different periods than anticipated; (xxviii) the risk that EQRx’s restructuring efforts may adversely affect its programs and its ability to recruit and retain skilled and motivated personnel, and may be distracting to employees and management; and (xxix) the risk that EQRx’s restructuring or wind-down efforts may negatively impact its business operations and reputation with or ability to serve counterparties or may take longer to realize than expected, as well as each of Revolution Medicines’ and EQRx’s response to any of the aforementioned factors. Additional factors that may affect the future results of Revolution Medicines and EQRx are set forth in their respective filings with the U.S. Securities and Exchange Commission (the “SEC”), including each of Revolution Medicines’ and EQRx’s most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC’s website at www.sec.gov. See in particular Item 1A of Revolution Medicines’ Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 under the heading “Risk Factors,” and Item 1A of each of EQRx’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2023 and June 30, 2023 under the headings “Risk Factors.” The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning Revolution Medicines and EQRx and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. Readers should also carefully review the risk factors described in other documents that Revolution Medicines and EQRx file from time to time with the SEC. Except as required by law, each of Revolution Medicines and EQRx assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Additional Information and Where to Find It

In connection with the proposed transaction, Revolution Medicines and EQRx filed with the SEC and mailed or otherwise provided to their respective security holders a joint proxy statement/prospectus regarding the proposed transaction (as amended or supplemented from time to time, the “Joint Proxy Statement/Prospectus”). INVESTORS AND REVOLUTION MEDICINES’ AND EQRX’S RESPECTIVE SECURITY HOLDERS ARE URGED TO CAREFULLY READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF REVOLUTION MEDICINES AND EQRX WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION.

Revolution Medicines’ investors and security holders may obtain a free copy of the Joint Proxy Statement/Prospectus and other documents that Revolution Medicines files with the SEC (when available) from the SEC’s website at www.sec.gov and Revolution Medicines’ website at ir.revmed.com. In addition, the Joint Proxy Statement/Prospectus and other documents filed by Revolution Medicines with the SEC (when available) may be obtained from Revolution Medicines free of charge by directing a request to Morrow Sodali LLC at RVMD@info.morrowsodali.com.

EQRx’s investors and security holders may obtain a free copy of the Joint Proxy Statement/Prospectus and other documents that EQRx files with the SEC (when available) from the SEC’s website at www.sec.gov and EQRx’s website at investors.eqrx.com. In addition, the Joint Proxy Statement/Prospectus and other documents filed by EQRx with the SEC (when available) may be obtained from EQRx free of charge by directing a request to EQRx’s Investor Relations at investors@eqrx.com.

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

Revolution Medicines, EQRx and their respective directors, executive officers, other members of management, certain employees and other persons may be deemed to be participants in the solicitation of proxies from the security holders of Revolution Medicines and EQRx in connection with the proposed transaction. Security holders may obtain information regarding the names, affiliations and interests of Revolution Medicines’ directors and executive officers in Revolution Medicines’ Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 27, 2023, and Revolution Medicines’ definitive proxy statement on Schedule 14A for its 2023 annual meeting of

stockholders, which was filed with the SEC on April 26, 2023. To the extent holdings of Revolution Medicines’ securities by Revolution Medicines’ directors and executive officers have changed since the amounts set forth in such proxy statement, such changes have been or will be reflected on subsequent Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC. Security holders may obtain information regarding the names, affiliations and interests of EQRx’s directors and executive officers in EQRx’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 23, 2023, and in certain of EQRx’s Current Reports on Form 8-K. To the extent holdings of EQRx’s securities by EQRx’s directors and executive officers have changed since the amounts set forth in such Annual Report on Form 10-K, such changes have been or will be reflected on subsequent Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such individuals in the proposed transaction is included in the Joint Proxy Statement/Prospectus relating to the proposed transaction filed with the SEC. These documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov, Revolution Medicines’ website at www.revmed.com and EQRx’s website at www.eqrx.com.

Investors & Media Contact:

Erin Graves

650-779-0136

egraves@revmed.com

EX-101.SCH 3 rvmd-20231101.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rvmd-20231101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rvmd-20231101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g527979g1101113455835.jpg GRAPHIC begin 644 g527979g1101113455835.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 01, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001628171
Document Type 8-K
Document Period End Date Nov. 01, 2023
Entity Registrant Name Revolution Medicines, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39219
Entity Tax Identification Number 47-2029180
Entity Address, Address Line One 700 Saginaw Drive
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94063
City Area Code 650
Local Phone Number 481-6801
Written Communications true
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, $0.0001 par value per share
Trading Symbol RVMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d527979d8k_htm.xml IDEA: XBRL DOCUMENT 0001628171 2023-11-01 2023-11-01 false 0001628171 8-K 2023-11-01 Revolution Medicines, Inc. DE 001-39219 47-2029180 700 Saginaw Drive Redwood City CA 94063 650 481-6801 true false false false Common stock, $0.0001 par value per share RVMD NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " #].&%799!YDAD! #/ P $P @ &K$@ 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #U$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d527979d8k.htm rvmd-20231101.xsd rvmd-20231101_lab.xml rvmd-20231101_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d527979d8k.htm": { "nsprefix": "rvmd", "nsuri": "http://www.revolutionmedicines.com/20231101", "dts": { "inline": { "local": [ "d527979d8k.htm" ] }, "schema": { "local": [ "rvmd-20231101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "rvmd-20231101_lab.xml" ] }, "presentationLink": { "local": [ "rvmd-20231101_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "report": { "R1": { "role": "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-11-01_to_2023-11-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d527979d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-11-01_to_2023-11-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d527979d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.revolutionmedicines.com//20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-23-267696-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-267696-xbrl.zip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end